Acquired hemophilia in the elderly

Blood Disorders in the Elderly

Volumn , Issue , 2007, Pages 387-405

  Baudo, Francesco ^a   De Cataldo, Francesco ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927061781     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545238.027     Document Type: Chapter

References (129)

1. Green D, Lechner K. A survey of 215 non-haemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
2. Hoyer LW. Factor VIII inhibitors. Curr Opin Hematol 1995; 2: 365-71.
3. Morrison AE, Ludlam CA. Acquired haemophilia and its treatment. Br J Haematol 1995; 89: 231-6.
4. Di Bona E, Schiavoni M, Castaman G, Ciavarella N, Rodeghiero F. Acquired hemophilia: experience of two Italian centers with 17 new cases. Haemophilia 1997; 3: 183-8.
5. Hoyer LW, Gawryl MS, de la Fuente B. Immunological characterization of factor VIII inhibitors. In Hoyer LW, ed, Factor VIII Inhibitors (New York, NY: Liss, 1984), 73-85.
6. Shapiro SS, Hultin M. Acquired inhibitors to blood coagulation factors. Semin Thromb Hemost 1975; 1: 336-85.
7. Lottenberg R, Kentro TB, Kitchens CS. Acquired haemophilia: a natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
8. Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired FVIII: C inhibitors. Br J Haematol 1981; 48: 636-42.
9. Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-8.
10. Morrison AE, Ludlam CA, Kessler CM. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-20.
11. Green D, Rademaker AW, Briet E. A prospective randomized trial of prednisolone and cyclophosphamide in the treatment of patients with factor VIII antibodies. Thromb Haemost 1993; 70: 753-7.
12. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86: 797-804.
13. Söhngen D, Specker C, Bach D, et al. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol 1997; 74: 89-93.
14. Bossi P, Cabane J, Ninet J, et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105: 400-8.
15. Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired haemophilia in a hemophilia centre over 28-year period. Clin Lab Haematol 2000; 22: 275-8.
16. Grünewald M, Beneke H, Güthner C, Germowitz A, Brommer A, Griesshammer M. Acquired haemophilia: experiences with a standardized approach. Haemophilia 2001; 7: 164-9.
17. Delgado J, Villar A, Jimenez-Yuste V, Gago J, Quintana M, Hernandez-Navarro F. Acquired hemophilia: a single-center survey with emphasis on immunotherapy and treatment-related side-effects. Eur J Haematol 2002; 69: 158-64.
18. Baudo F, Mostarda G, de Cataldo F. Acquired factor VIII and factor IX inhibitors: survey of the Italian haemophilia centers (AICE). Haematologica 2003; 88 (Suppl 12): 93-9.
19. Nemes L, Pitlik E. Ten years experience with immunotolerance induction therapy in acquired hemophilia. Haematologica 2003; 88 (Suppl 12): 106-10.
20. Huang YW, Saidi P, Philipp C. Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases. Haemophilia 2004; 10: 713-21.
21. Baudo F, de Cataldo F, Gaidano G. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica 2004; 89: 759-61.
22. Collins P, Macartney N, Davies R, Lees S, Giddins J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124: 86-90.
23. Sallah S. Treatment of acquired hemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-73.
24. Holme PA, Brosstad F, Tjønnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11: 510-15.
25. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmö Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105: 2287-93.
26. Kessler CM, Ludlam. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. Semin Hematol 1993; 30 (Suppl 1): 22-7.
27. Hultin MB, Shapiro SS, Bowman HS, et al. Immunosuppressive therapy of factor VIII inhibitors. Blood 1976; 48: 95-108.
28. Haj M, Dasani H, Kundu S, Mohiti U, Collins PW. Acquired haemophilia A may be associated with clopidogrel. BMJ 2004; 329: 323.
29. O’Reilly RA, Hamilton RD. Acquired hemophilia, meningioma and diphenylhydantoin therapy. J Neurosurg 1980; 53: 600-5.
30. Stewart AJ, Manson LM, Dasani H, Beddall A, Collins P, Shima M. Acquired haemophilia in recipients of depot thioxanthenes. Haemophilia 2000; 6: 709-12.
31. Sallah S, Wan JY. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine. Thromb Haemost 2001; 86: 1119-21.
32. Burnet SP, Duncan EM, Lloyd JV, Han P. Acquired haemophilia in South Australia: a case series. Intern Med J 2001; 31: 556-9.
33. Hauser I, Lechner K. Solid tumors and FVIII antibodies. Thromb Haemost 1999; 82: 1005-7.
34. Sallah S, Nguten NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000; 124: 730-4.
35. Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Cancer 2001; 91: 1067-74.
36. Bajaj SP, Rapaport SI, Barclay S, Herbst KD. Acquired hypoprothrombinemia to non-neutralizing antibodies to prothrombin; mechanism and management. Blood 1985; 65: 1538-43.
37. Wong RS, Lau FY, Cheng G. Successful treatment of acquired hypoprothrombinemia without associated lupus anticoagulant using intravenous immunoglobulin. Haematologica 2001; 86: 551.
38. Favaloro EJ, Posen J, Ramakrishna R, et al. Factor V inhibitors: rare or not uncommon? A multi-laboratory investigation. Blood Coag Fibrinolysis 2004; 15: 637-47.
39. Collins HW, Gonzalez MF. Acquired factor IX inhibitor in a patient with adenocarcinoma of the colon. Acta Haematol 1984; 71: 49-52.
40. Miller K, Neely JE, Krivit W, Edson JR. Spontaneous acquired factor IX inhibitor in a nonhemophiliac child. J Pediatr 1978; 93: 232-4.
41. Largo R, Sigg P, von Felten A, Straub PW. Acquired factor IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol 1974; 26: 129-40.
42. Mulhare PE, Tracy PB, Golden EA, Branda RF, Bovill EG. A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X. Am J Clin Pathol 1991; 96: 196-200.
43. Smith SV, Liles DK, White GC 2nd, Brecher ME. Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy. Am J Hematol 1998; 57: 245-52.
44. Bern MM, Sahud M, Zhukov O, Qu K, Mithchell W. Treatment of factor XI inhibitor using recombinant activate factor VIIa. Haemophilia 2005; 11: 20-5.
45. Goodrick MJ, Prentice AG, Copplestone JA, Pamphilon DH, Boon RJ. Acquired factor XI inhibitor in chronic lymphocytic leukaemia. J Clin Pathol 1992; 45: 352-3.
46. Reece EA, Clyne LP, Romero R, Hobbins JC. Spontaneous factor XI inhibitors. Seven additional cases and review of the literature. Arch Intern Med 1984; 144: 525-9.
47. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipids and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
48. Saenko EL, Ananyeva NM, Kouiavskaia DV, et al. Hemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia 2002; 8: 1-11.
49. Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-26.
50. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phospholipids binding site. Blood 1995; 86: 1811-19.
51. Prescott R, Nakai H, Saenko EV, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 3663-71.
52. Sallah S, Aledort L. Treatment of patients with acquired inhibitors. J Thromb Haemost 2005; 3: 595-7.
53. Dykes AC, Walker ID, Lowe GDO, Tait RC. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia 2001; 7: 160-3.
54. Rubinger M, Houston DS, Schwetz N, Woloschuk DMM, Israel SJ, Johnston JB. Continuous infusion of porcine factor III in the management of patients with factor VIII inhibitors. Am J Hematol 1997; 56: 112-18.
55. Saxena R, Mishra DK, Kashyap R, Choudhry VP, Mahapatra M, Bhargava M. Acquired haemophilia: a study of ten cases. Haemophilia 2000; 6: 78-83.
56. Lindgren A, Wadenvik H, Tengborn L. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. Haemophilia 2002; 8: 644-8.
57. Grawril NS, Hoyer LW Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-9.
58. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulant: an update. Thromb Haemost 1995; 74: 1185-90.
59. Ludlam CA, Morrison AE, Kessler C. Treatment of acquired hemophilia. Semin Hematol 1994; 31 (Suppl 4): 16-19.
60. Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol 1996; 9: 331-54.
61. Hay CRM. Acquired hemophilia. Baillieres Clin Haematol 1998; 11: 287-303.
62. Kessler CM, Nemes L. Acquired inhibitors to factor VIII. In Rodriguez-Merchan EC, Lee CA, eds, Inhibitors in Patients with Haemophilia (Oxford: Blackwell, 2002), 98-112.
63. Ewenstein BM, Putnam KG, Bohn RL. Nonhemophilic inhibitors of coagulation. In Kitchens CS, Alving BM, Kessler CM, eds, Consultative Hemostasis and Thrombosis (Philadelphia, PA: Saunders, 2002), 75-90.
64. Baudo F, de Cataldo F. Acquired hemophilia: a critical syndrome. Haematologica 2004; 89: 96-100.
65. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
66. Kasper CK. The therapy of factor VIII inhibitors. Prog Hemostas Thromb 1989; 9: 57-86.
67. Lusher JM. Use of factor VIII by-passing agents to control bleeding in patients with acquired factor VIII inhibitors. In Kessler CM, ed, Acquired Hemophilia, 2nd edn (Princeton, NJ: Excerpta Medica, 1995), 113-29.
68. Hay CRM, Baglin TP, Collins PW, Hill FGH, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors Organization (UKHCDO). Br J Haematol 2000; 111: 78-90.
69. Association of Hemophilia Clinic Directors of Canada. Suggestions for the management of factor VIII inhibitors. Haemophilia 2000; 6 (Suppl 1): 52-9.
70. Gringeri A, Mannucci PM. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-19.
71. Ludlam CA, Mannucci PM, Powderly WG on behalf of the European Interdisciplinary Working Group. Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. Haemophilia 2005; 11: 433-7.
72. Blatt PM, White GC 2nd, McMillan CW, Roberts HR. Treatment of antifactor VIII antibodies. Thromb Haemost 1977; 38: 514-23.
73. Kessler CM. An introduction to factor VIII inhibitors. The detection and quantitation. Am J Med 1991;91 (Suppl 5A): 33-6.
74. Solymoss S. Post partum acquired factor VIII inhibitors: results of a survey. Am J Hematol 1998; 59: 1-4.
75. Bona RD, Ribeno M, Klatsky AV, Panek S, Magnifico H, Rickles FR. Continuous infusion of porcine FVIII for the treatment of patients with factor VIII inhibitors. Semin Hematol 1993; 30 (Suppl 1): 32.
76. Gribble J, Garvey MB. Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII. Haemophilia 2000; 6: 482-6.
77. Gatti L, Mannucci PM. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost 1984; 51: 379-84.
78. Hay CRM, Bolton-Maggs P. Porcine factor VIIIC in the management of patients with factor VIII inhibitors. Transf Med Rev 1991; 5: 145-51.
79. Gringeri A, Santagostino E, Tradati F. Adverse effects of treatment with porcine FVIII. Thromb Haemost 1991; 65: 245-7.
80. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressin induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000; 106: 107-16.
81. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressina for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692-6.
82. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease. Br J Haematol 1981; 47: 283-93.
83. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
84. Muhm M, Grois N, Kier P, et al. 1-Deamino-8-darginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor. Haemostasis 1990; 20: 15.
85. De la Fuente, Panek S, Hoyer LW. The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in non haemophilic patient with an acquired type II inhibitor. Br J Haematol 1985; 59: 127.
86. Naorose-Abidi SM, Bond LR, Chitolie A, Bevan DH. Desmopressin therapy in patients with acquired factor VIII inhibitors. Lancet 1988; 1: 366.
87. Mudad R, Kane WH. DDAVP in acquired haemophilia A: case report and review of the literature. Am J Hematol 1993; 43: 295-9.
88. Sultan Y, Maisonneuve P, Kazatchkine MD, Nydegger UE. Anti-idiotypic suppression of auto-antibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-8.
89. Sultan Y. Acquired hemophilia and its treatment. Blood Coagul Fibrinolysis 1997; 8 (Suppl 1): S15-S18.
90. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86: 797-804.
91. Negrier C, Goudemand J, Sultan Y, et al. Multicentre retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1977; 77: 1113-19.
92. Sjamsoedin LJ, Heijen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex (FEIBA) on joint and muscle bleeding in patients with hemophilia and antibodies for factor VIII. A double blinded clinical trial. N Engl J Med 1981; 305: 717-21.
93. Lusher JM, Shapiro SS, Palascek JE, et al. Efficacy of prothrombin complex concentrates in haemophiliacs with antibodies to factor VIII. A multicentre therapeutic trial. N Engl J Med 1980; 303: 421-5.
94. Turecek PL, Varadi K, Gritsch H et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999; 77 (Suppl 1): 72S-79S.
95. White GC. Seventeen years’ experience with Autoplex/Autoplex T. Evaluation of inpatients with severe haemophilia A and factor VIII inhibitors at a major haemophilia center. Haemophilia 2000; 6: 508-12.
96. Tjønnfjord GE, Brinch L, Gedde-Dahl III T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA®) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
97. Chavin SI, Siegel DM, Rocco TA, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med 1988; 85: 245-9.
98. Mizon P, Goudemand J, Jude B, Marey A. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol 1992; 64: 309-11.
99. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors: benefit and limitations. Semin Hematol 1994; 31: 49-52.
100. Lisman T, De Groot G. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138-9.
101. Robert HR, Monroe DM, White G. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64.
102. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997; 78: 1463-7.
103. Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with Haemophilia A or B with inhibitors. Haemostasis 1998; 28: 93.
104. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX deficiency. Hemophilia 1999; 5: 253-9.
105. Baudo F, Redaelli R, Caimi TM, Mostarda G, Somaini G, de Cataldo F. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and the fibrinolytic systems without clinical complications. Thromb Res 2000; 99: 21-4.
106. Hay CRM. Thrombosis and recombinant factor VIIa. J Thromb Haemost 2004; 2: 1698-9.
107. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
108. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitory bypass activity. J Thromb Haemost 2004; 2: 1700-8.
109. Abshire T. The safety of recombinant factor VIIa: a reply to rebuttal. J Thromb Haemost. 2004; 2: 2079.
110. Sallah S, Isaksen M, Seremetis S, Payne Rojkjaer L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs factor VIII inhibitory bypass activity. A rebuttal. J Thromb Haemost 2005; 3: 820-2.
111. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs factor VIII inhibitory bypass activity: a rebuttal. J Thromb Haemost 2005; 3: 822.
112. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VII. JAMA 2006; 295: 293-8.
113. Nilsson I, Sundqvist SB, Freiburghaus C. Extracorporeal protein A sepharose and specific affinity chromatography for removal of antibodies. In Hoyer LW, ed, Factor VIII Inhibitors (New York, NY: Liss, 1984), 225-41.
114. Négrier C, Dechavanne M, Alfonsi F, Tremisi PJ. Successful treatment of acquired factor VIII antibody by extracorporeal immunoadsorption. Acta Haematol 1991; 85: 107-10.
115. Gjörstrup P, Berntorp E, Larsson L, Nilsson IM. Kinetic aspects of removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption. Vox Sang 1991; 61: 244-50.
116. Knöbl P, Derfler K. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 1999; 77 (Suppl 1): 57S-64S.
117. Jansen M, Schmaldienst S, Banyai, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig Therasorb). Br J Haematol 2001; 112: 91-7.
118. Feinstein DI, Green D, Federici AB, Goodnight SH. Diagnosis and management of patients with spontaneously acquired inhibitors of coagulation. Hematology 1999; American Society of Hematology Education Program Book, 192-208.
119. Bussi L, Baudo F, de Cataldo F. Factor VIII concentrate and cyclophosphamide in patients with factor VIII inhibitors. Blood 1974; 44: 767.
120. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired hemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
121. Schulman S, Langevitz P, Livneh A, Martinowitz U, Seligsohn U, Varon D. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1995; 76: 344-6.
122. Brox AG, Laryea H, Pelletier M. Successful treatment of acquired factor VIII inhibitors with cyclosporin. Am J Hematol 1998; 57: 87-8.
123. Maclean PS, Tait RC, Lowe GDO, Walker ID, McColl MD. Successful elimination of factor VIII inhibitors using cyclosporin. Br J Haematol 2003; 122: 1024-6.
124. Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood 2003; 101: 943-5.
125. Stachnik JM. Rituximab in the treatment of acquired hemophilia. Ann Pharmacother 2006; 40: 1151-7.
126. Sperr WR, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica 2007; 92: 66-71.
127. Huth-Kuhne A, Ehrenforth S, Scharrer I, Zimmermann R. A new treatment option for patients with acquired hemophilia A: the modified Malmö-Heidelber protocol. Thromb Haemost 2001; 86: 3364a.
128. Hess L, Zeitler H, Unkrig C, et al. Modified Bonn-Malmö protocol (MBM-P). Haematologica 2003;88 (Suppl. 12): 78-85.
129. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmö protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105: 2287-93.